Zinc Deficiency may Synergies the Taste Impairment of Terbinafine: A Case Report
DOI:
https://doi.org/10.32628/IJSRST241161135Keywords:
Terbinafine, Zinc deficiency, Tinea corporis, Taste impairmentAbstract
Terbinafine, an oral antifungal belonging to the allylamine class, was introduced in 1991 and is now widely used for both topical and systemic treatment of fungal infections, including tinea corporis. An eighteen-year-old male patient presented with a skin infection diagnosed as tinea corporis, with a known history of acrodermatitis enteropathica, an inherited zinc deficiency disorder. Zinc is an essential component for normal taste perception. It is initiated as antifungal therapy by administering 250 mg of oral terbinafine (Sebifin) daily. During a follow-up appointment two weeks into the treatment, the patient reported altered taste sensations, including a diminished ability to taste bitter and sour flavours and a partial loss of sweet and salty taste. The taste disorder began five days after starting the medication. Suspecting terbinafine-induced taste impairment, the drug was immediately discontinued. The patient's taste function fully recovered five days after discontinuation, indicating the reversibility of this adverse effect. This case highlights the importance of monitoring for potential side effects during antifungal therapy, particularly in patients with underlying conditions such as acrodermatitis enteropathica (zinc deficiency).
Downloads
References
Sinha R, Sharma P, Kumar P, Kuchhal V. Terbinafine-induced taste impairment-report of two cases. *Contact Dermatitis* 2012;22(4):292-294.
Stricker BH, de Jong PA, Schreuder F, Bijlmer-Iest JC, Herrmann WA, van Ulsen J. Loss of taste sensation in terbinafine administration. *Contact Dermatitis* 1992;136(49):2438-2440.
Duxbury AJ, Oliver RJ, Pemberton MN. Persistent impairment of taste associated with terbinafine. *Contact Dermatitis* 2000;188(6):295-296. DOI: https://doi.org/10.1038/sj.bdj.4800461
Ricardo JW, Lipner SR. Taste and smell disturbances induced by terbinafine: A systematic review of the literature. *Contact Dermatitis* 2021;85(3):554-561. DOI: https://doi.org/10.1016/j.jaad.2021.06.151
Leung AKC, Lam JM, Leong KF, Hon KL. Tinea corporis: an updated review. *Contact Dermatitis* 2020;9:5-6. DOI: https://doi.org/10.7573/dic.2020-5-6
Lal NR, Basu D, Saha A, Ghosh R, Verma R, Bandyopadhyay D. Efficacy and safety of 250 mg versus 500 mg oral terbinafine in the treatment of tinea corporis and cruris: A randomised, assessor-blinded comparative study. *Contact Dermatitis* 2022;89(5):665-671. DOI: https://doi.org/10.25259/IJDVL_74_2022
Downloads
Published
Issue
Section
License
Copyright (c) 2024 International Journal of Scientific Research in Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.